

Published in final edited form as:

*J Am Chem Soc.* 2011 January 26; 133(3): 559–566. doi:10.1021/ja108441d.

## Core-clickable PEG-*branch*-azide bivalent-bottle-brush polymers by ROMP: grafting-through and clicking-to

Jeremiah A. Johnson, Ying Y. Lu, Alan O. Burts, Yeon-Hee Lim, M.G. Finn, Jeffrey T. Koberstein, Nicholas J. Turro, David A. Tirrell, and Robert H. Grubbs

Division of Chemistry and Chemical Engineering, California Institute of Technology, 1200 E. California Blvd., Pasadena, California 91125, Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, Department of Chemical Engineering, Columbia University, 500 West 120<sup>th</sup> Street, New York, New York, 10027, and Department of Chemistry, Columbia University, 3000 Broadway, New York, New York 10027

### Abstract

The combination of highly efficient polymerizations with modular “click” coupling reactions has enabled the synthesis of wide variety of novel nanoscopic structures. Here we demonstrate the facile synthesis of a new class of clickable, branched nanostructures, polyethylene glycol (PEG)-*branch*-azide bivalent-brush polymers, facilitated by “graft-through” ring-opening metathesis polymerization (ROMP) of a branched norbornene-PEG-chloride macromonomer followed by halide-azide exchange. The resulting bivalent-brush polymers possess azide groups at the core near a polynorbornene backbone with PEG chains extended into solution; the structure resembles a unimolecular micelle. We demonstrate copper-catalyzed azide-alkyne cycloaddition (CuAAC) “click-to” coupling of a photocleavable doxorubicin (DOX)-alkyne derivative to the azide core. The CuAAC coupling was quantitative across a wide range of nanoscopic sizes (~6 – ~50 nm); UV photolysis of the resulting DOX-loaded materials yielded free DOX that was therapeutically effective against human cancer cells.

### Introduction

The explosion of nanoscience is fuelled by problems that require nanoscale solutions and by the inherent challenges of nanoscale synthesis.<sup>1–3</sup> In drug delivery, for example, plasma clearance time of a polymer-drug conjugate is closely linked to its nanoscopic size; materials smaller than 10 nm are excreted rapidly whereas larger materials often display significantly longer retention times.<sup>3–9</sup> Nanoscopic architecture also plays an important role in determining *in vivo* retention time.<sup>10–12</sup> Branched polymeric structures such as dendrimers, star polymers, bottle-brush polymers, and hyperbranched polymers generally display longer *in vivo* retention times compared to their linear polymer analogues.<sup>11,13</sup> A wealth of research attention has focused on synthetic approaches to branched, stimuli-responsive, nanoscopic materials that possess orthogonal functionality for incorporation of therapeutic, imaging, and targeting molecules.<sup>14–25</sup>

The most widely studied branched macromolecules for drug delivery are dendrimers; their nanoscale, monodisperse, multi-valent structures provide functional handles for elaboration

rhg@caltech.edu; tirrell@caltech.edu.

Supporting information available. Synthetic procedures, spectral data, liquid chromatography methods, details of cell viability studies. This information is available free of charge via the Internet at <http://pubs.acs.org/>.

with bioactive groups of interest.<sup>26–28</sup> One factor that limits widespread application of dendrimers is synthetic difficulty. Though recent synthetic advances are impressive,<sup>16,29–32</sup> it remains a challenge to prepare functionally diverse dendrimers of variable sizes. To overcome this challenge, researchers have appended linear polymers to dendrimers<sup>33–36</sup> or prepared linear polymers with dendritic fragments attached to their sidechains. The latter “dendronized linear polymers” have attracted attention as nanoscopic building blocks; their cylindrical shapes can provide important advantages in nanoscale fabrication when compared to spherical dendrimers.<sup>37–43</sup> Similar nanoscale structures can be formed from bottle-brush-polymers that carry long chains grafted at high density to linear polymer backbones.<sup>44–63</sup> Bottle-brush polymers are prepared by graft-to, graft-from, or graft-through methodologies. The graft-to strategy requires an efficient coupling reaction to attach a functional molecule to every monomer unit of a linear polymer; “click”<sup>64</sup> reactions such as the copper-catalyzed azide-alkyne cycloaddition<sup>65,66</sup> (CuAAC) and thiol-ene coupling have proven useful in this regard.<sup>43,46,67–70</sup> Graft-from and graft-through methodologies require highly efficient polymerization reactions capable of initiation and propagation in sterically-demanding environments.<sup>48,51–53,71</sup> Recent developments in efficient, controlled polymerization coupled with new click reactions provide materials chemists with the tools to generate novel functional nanoscopic materials.<sup>72–77</sup>

Ring-opening metathesis polymerization (ROMP) of strained alkene- (e.g. norbornene)-terminated macromonomers (MM) initiated by ruthenium *N*-heterocyclic carbene complexes (e.g. **1**, Figure 1) has recently proven useful for graft-through synthesis of functional bottle-brush polymers;<sup>50,78–83</sup> fast initiation leads to low polydispersities (PDIs) while release of ring strain provides the driving force for high conversion in these systems. Although catalyst **1** is incompatible with azides and alkynes, its functional group tolerance enables use of monomers bearing azide and alkyne precursors that are easily converted to the requisite click groups after polymerization. Binder and coworkers used ROMP combined with CuAAC to append various small molecules to clickable linear polymers.<sup>84,85</sup> We have used ROMP in conjunction with CuAAC to generate cyclic polymers by end-to-end coupling.<sup>86</sup> To our knowledge, there are no examples of water-soluble brush polymers prepared by graft-through ROMP that are subsequently functionalized via click reactions. Such a strategy combines the benefits of ROMP for graft-through brush polymer synthesis with the modularity and efficiency of CuAAC for clicking-to; branched nanoscopic polymers with easily addressable functional groups can be rapidly prepared over a wide range of sizes simply by altering the ratio of catalyst to MM.

In this report we demonstrate the sequential combination of graft-through- and click-to synthetic strategies to generate a clickable polyethylene glycol (PEG)-azide branched polymer material: a bivalent-bottle-brush polymer (Figure 1). Graft-through ROMP of a PEG-chloride macromonomer (Figure 1, Scheme 1, **6**) gave bivalent-brush polymers of varying nanoscopic sizes. These materials resemble 1<sup>st</sup>-generation dendronized polymers with branch points located near the linear polymer backbone (Figure 1); attached on one side of the branch point is a linear polymer and on the other side a small molecule (e.g. a drug). This design incorporates a water-soluble PEG domain that extends into solvent and a hydrophobic alkyl chloride near the core. We hypothesize that PEG attachment to one branch of these bivalent-branch polymers will confer the biocompatibility widely observed for PEGylated systems.<sup>6,87</sup> Core-functionalized nanomaterials have been elaborated with functional small molecules by click chemistry;<sup>88–92</sup> in this work we convert the core alkyl chlorides to azides by treatment with sodium azide. Then, we utilize CuAAC to couple doxorubicin (**DOX**), to the core via a photo-cleavable nitrobenzyloxycarbonyl (NBOC) linker. The latter enables controlled release of free **DOX** in response to long-wavelength (~365 nm) ultraviolet (UV) light; we demonstrate that released **DOX** is therapeutically active against human cancer cells in culture.

## Results and Discussion

### Synthesis of MM 6

Clickable bivalent PEG brush polymers can be generated from an MM containing a strained norbornene derivative for ROMP, a PEG chain, and a functional group suitable for CuAAC (Figure 1, Scheme 1). Since neither azides nor alkynes are compatible with catalyst **1**, we designed MM **6** to carry an alkyl chloride for facile conversion to an azide in a post-ROMP modification step. We incorporated a 6-carbon spacer between the strained norbornene moiety and the tertiary amide branch point to reduce steric hindrance between the growing polymer chain end and the branched side-chains. This spacer may also facilitate subsequent sidechain modification reactions, such as chloride to azide conversion and CuAAC. MM **6** was obtained in five steps from *exo-N*-(6-hydroxyhexyl)-5-norbornene-2,3-dicarboximide (**norb-C6OH**, Scheme 1). The synthesis commenced with Swern oxidation of **norb-C6OH** to give aldehyde **2**. Reductive amination using **2** and 3-chloropropylamine hydrochloride gave secondary amine **3**, which was readily converted to acid **4** by treatment with succinic anhydride. Reaction of **4** with *N*-hydroxysuccinimide (NHS) in the presence of *N*-(3-dimethylaminopropyl)-*N*-ethylcarbodiimide hydrochloride (EDC) and catalytic 4-(dimethylamino)pyridine (DMAP) gave NHS ester **5**. We have prepared **5** on a multi-gram scale and expect it to be useful for the preparation of a variety of multifunctional ROMP monomers. In this work, commercially available 3 kDa PEG-NH<sub>2</sub> was treated with a slight excess of **5** to give MM **6**. Excess **5** was used to ensure complete conversion of every PEG-amine to amide **6**; the only polymeric species in the final reaction mixture was **6** and it was easily purified via repeated precipitation in diethyl ether. The <sup>1</sup>H NMR, <sup>13</sup>C NMR, and MALDI spectra for MM **6** are provided in the supporting information.

### Graft-through ROMP of **6** and halide-azide exchange to generate *n*N<sub>3</sub> bivalent-brush polymers

We pursued a one-pot synthetic strategy to rapidly generate a library of azide-functional brush polymers (*n*N<sub>3</sub>) with variable number-average degrees of polymerization (DP) and hydrodynamic radii. A strength of this approach is the ease of generating branched functional materials of variable sizes rapidly and efficiently; each of the polymers described here was prepared by adding an aliquot of catalyst **1** to a vial containing MM **6**, allowing 60 min for ROMP to proceed, quenching the polymerization by addition of ethyl vinyl ether, solvent exchange, and finally treatment with sodium azide (Scheme 2). The first several steps were performed within a few hours whereas the final step, attaching azides to the polymer sidechains, was left for 48 h to ensure high conversion.

The polymer characterization data in Table I demonstrate that ROMP of **6** is well-controlled up to the highest DP tested; a small amount of catalyst deactivation and/or experimental error may explain the larger-than-expected DP for the **400N<sub>3</sub>** samples. In general, polymers with low polydispersities and molecular weights defined by the ratio of **6**:**1** were obtained. The GPC traces for all samples (Figure 2A) show monomodal molecular weight distributions and very high (>95%) MM conversions. All of the polymers were highly soluble (>100 mg/mL) in water; aqueous DLS measurements (Table I, Figure 3B) confirm that their nanoscopic dimensions increased with DP and were tunable over a broad range (radii from 3 – 25 nm) of relevant sizes for drug delivery applications. Furthermore, DLS (Figure 2B) shows that the particle size distributions are monomodal.

Graft-through ROMP ensures that every side chain unit possesses both a PEG chain and an alkyl chloride; the weight percentage of chloride is independent of DP. It follows that if every chloride is converted to an azide then the weight percentage of azide is also independent of DP. One may expect sidechain modification reactions with bivalent-brush

polymers to display DP-dependent conversion; perhaps increased DP would lead to lower reaction yields because of increased steric hindrance. We have found that for both chloride-azide exchange and CuAAC reactions there is no apparent difference in reaction yield across the DP values studied here. Figure 3 shows the FTIR spectra for a subset of  $n\text{N}_3$  polymers normalized to the PEG ether (C-O-C antisymmetric stretch) absorbance at  $\sim 1100\text{ cm}^{-1}$ . The intensities of the characteristic azide antisymmetric stretch ( $\sim 2100\text{ cm}^{-1}$ ) are the same for each DP, which suggests that the azide:PEG ratio is the same for each sample and that the chloride-azide exchange reaction occurred with equal efficiency for each DP value.

### Click chemistry using DOX-NBOC-alkyne **9**

The ultimate application of these  $n\text{N}_3$  bivalent-brush polymers is defined by how they are decorated with functional groups. For drug delivery applications one can imagine clicking a drug-alkyne derivative attached via a cleavable linker group (Figure 1). The resulting polymer would undergo controlled drug release in response to an external stimulus leaving the brush polymer scaffold intact. In this work, we designed **9** for controlled release of **DOX** in response to UV light after click coupling to the  $n\text{N}_3$  polymer scaffold (Scheme 3). Photo-initiated release from macromolecules provides a means for site-specific, controlled drug delivery and could potentially complement traditional phototherapeutic methods.<sup>93–103</sup> Though placement of azide groups near the core of these bivalent-brush polymers should allow PEG to extend into solution and increase the biocompatibility of these materials, a buried location may make them difficult to functionalize with subsequent reactions. Anticipating this challenge was one reason we chose two highly efficient reactions, halide-azide exchange and CuAAC, as the modification reactions; as described above CuAAC has proven useful for quantitative attachment of small molecules to the side chains of ROMP polymers<sup>84,85</sup> and we expected that it would provide the best opportunity for high-yield coupling of sterically-demanding alkyne reagents to bivalent-branch polymers. There are a variety of CuAAC conditions throughout the literature and the catalyst/ligand/solvent system depends on the application,<sup>104–107</sup> perhaps the most impressive applications of CuAAC are in the field of bioconjugation where the requisite azide and alkyne functional groups are present in very low concentration amongst a number of other reactive groups.<sup>108–111</sup> The Finn laboratory recently reported optimized CuAAC conditions for bioconjugation which utilize a new accelerating ligand THPTA (Scheme 4).<sup>112</sup> Aqueous CuAAC was found to proceed orders of magnitude faster with THPTA than in the absence of a ligand. Since these  $n\text{N}_3$  bivalent-brush polymers are nanoscopic, narrowly-dispersed, water-soluble materials with buried functional groups, we envisioned CuAAC reactions to them as similar to bioconjugation reactions to proteins bearing multiple azide or alkyne groups. After initial attempts without accelerating ligand, which led to  $< 20\%$  conversion after several days, we were pleased to find that addition of THPTA to the reaction mixture gave quantitative conversions. In a typical reaction, the polymer, THPTA (20 equiv. to azide), and alkyne **9** (1.05 equiv. to azide) were dissolved in 95%  $\text{H}_2\text{O}/5\%$  DMSO such that the concentration of alkyne **9** was 2 mM. Aqueous sodium ascorbate (1.0 M) was added followed by copper(II) sulfate (1.0 M); two more aliquots of aqueous copper sulfate and sodium ascorbate were added over 2 days such that their final amounts were 10 and 50 equivalents, respectively, relative to azide. The reactions were performed at  $40\text{ }^\circ\text{C}$  to achieve the maximum rate possible without inducing potential azide-olefin cycloaddition side reactions.<sup>84</sup>

Figure 4A (inset) depicts the CuAAC coupling of **9** to  $100\text{N}_3$  as monitored by liquid-chromatography mass-spectrometry (LC-MS). Compound **9** eluted at  $\sim 4.2$  min while **DOX**-loaded polymer eluted from  $\sim 3.5$  –  $\sim 4$  min. The unique absorbance of **DOX** ( $\sim 500$  nm) enables facile monitoring of the CuAAC reaction; the  $100\text{N}_3$  polymer does not absorb at 500 nm and therefore the growth of a new, broad polymer peak is attributed to CuAAC coupling of **9** to the polymer. The time-dependent LC-MS traces (Figure 4A, inset) show an

increasing polymer absorbance at the expense of the alkyne **9** absorbance until a final, very high (>97%) conversion is reached. As for the case with chloride-azide exchange, one may expect the CuAAC reaction progress to depend on DP. Figure 4A shows preparatory high-performance liquid chromatography (prep-HPLC) 500 nm absorbance traces for several crude *n*DOX polymers; the total ratio of *n*DOX:**9** is the same for each DP which again suggests that DP has little effect on the efficiency of reactions to these structures. The retention times for the *n*DOX polymers increase slightly for each DP indicating that polymer-column interactions are dependent on DP. The pure polymer fractions were collected and either lyophilized to dryness or concentrated before use in subsequent experiments. Figure 4B shows the FTIR spectrum of purified **50DOX** compared to that of **50N<sub>3</sub>**. The azide antisymmetric stretch at  $\sim 2100\text{ cm}^{-1}$ , present in the spectrum of **50N<sub>3</sub>**, is completely absent from the **50DOX** spectrum which suggests very high consumption of the azide group. Integration of the broad aromatic resonances in the  $^1\text{H}$  NMR spectrum of **50DOX** compared to the PEG methylene groups is in close agreement to that expected for fully DOX-functionalized polymer (Figure S5). The final DOX weight percentage for the functionalized polymers is 12.6%. As mentioned above, this value is independent of DP; it could be adjusted by varying the PEG length or the degree of branching in the MM precursor.

### Photorelease of DOX and cell culture studies

Having successfully coupled **9** to *n*N<sub>3</sub> we next studied the release of free DOX from the brush polymer in response to UV light ( $\sim 365\text{ nm}$ ). An aqueous solution of purified *n*DOX polymer was irradiated at 365 nm for a given time and subjected to LC-MS analysis. The progress of photorelease was monitored over 10 min by repeated irradiation and LC-MS; the data for **100DOX** are shown in Figure 5A. As irradiation time increased we observed a new peak at  $\sim 3\text{ min}$  that increased in intensity at the expense of the **100DOX** polymer peak. The new peak corresponds to the retention time and mass of free DOX. We also observed a small side product at  $\sim 3.6\text{ min}$  with a mass of 569 Da (labelled “\*” in Figure 5A), which is likely the result of intramolecular trapping of carbamic acid **10** to give cyclic carbamate **11**. Nevertheless, the major product of UV photolysis was free DOX; the photolysis yield after 10 min irradiation was  $\sim 70\%$  for all *n*DOX polymers which led us to examine the effectiveness of these materials against human cancer cells in cell culture.

We performed cell viability experiments using MCF-7 human breast cancer cells. Cells were treated with aqueous solutions of either free DOX or the corresponding *n*DOX polymer at various concentrations and irradiated for 10 min using 365 nm light or kept in the dark. The cells were then incubated in the dark for 24 h, washed twice, and incubated for another 24 h in fresh, drug-free growth medium. Cell viability was assessed using the MTT assay (see methods and materials for details). Data for *n* = 100 polymers (**100N<sub>3</sub>** and **100DOX**) are shown in Figure 5B (cell viability data for other *n* values is given in the supporting information). Free DOX, with and without UV irradiation, effectively killed the cells at 3–5  $\mu\text{M}$  while azide polymer **100N<sub>3</sub>** was non-toxic with and without light up to 100  $\mu\text{M}$ ; these data taken together suggest that under our conditions 10 min of 365 nm UV irradiation has no adverse affect on cell viability nor does it interrupt the cellular toxicity of DOX. None of the *n*DOX bivalent-brush polymers studied were toxic up to 50  $\mu\text{M}$  in the absence of UV irradiation; irradiation for 10 min yielded IC<sub>50</sub> values  $\sim 7\text{--}10\ \mu\text{M}$  which confirms that free DOX generated by photorelease is therapeutically active. The IC<sub>50</sub> values were not DP-dependent. This observation suggests that the *n*DOX polymers remain in the extracellular environment and upon photolysis free DOX is released and diffuses into the cell nucleus where it induces apoptosis. Though *in vitro* experiments do not show DP-dependent cytotoxicity, we expect that DP will affect *in vivo* trafficking and thus the overall utility of



these materials in drug delivery. Targeting groups could be appended to the periphery of these materials to promote trafficking into the cell.<sup>113</sup>

Here we have demonstrated the utility of a combined graft-through/click-to strategy for the synthesis of a new class of clickable, branched nanostructures: PEG-*branch*-azide bivalent-brush polymers. This approach makes use of the remarkable efficiency of ROMP for graft-through polymerization and the modular coupling power of click chemistry for polymer functionalization. A wide range of nanoscale sizes is accessible which will enable detailed structure/function correlation in biological settings. We are currently exploring applications for these materials in drug delivery. Design and synthesis of novel clickable linkers (e.g. longer wavelength-, pH-, and redox-cleavable), attachment of targeting moieties at the PEG periphery, incorporation of degradable units within the polymer backbone, and use of chain-transfer agents to append orthogonal groups selectively to the ends of these polymers are being studied. Furthermore, copolymerization of MMs like **6** with other monomers (such as a norbornene-alkyl halide small molecule) will provide access to new multiblock polymer structures with the potential for higher drug loadings.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank Dr. S. Virgil and Mr. S. Presolski for helpful advice. This work was supported by the National Institutes of Health (NIH, R01-GM31332), the Beckman Institute at Caltech (postdoctoral fellowship for J.A.J.), and the MRSEC program of the National Science Foundation (NSF) under award number DMR-0520565.

## References


1. Whitesides GM. *Small*. 2005; 1:172–179. [PubMed: 17193427]
2. Steigerwald ML, Brus LE. *Acc Chem Res*. 1990; 23:183–188.
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. *Nat Nanotechnol*. 2007; 2:751–760. [PubMed: 18654426]
4. Matsumura Y, Maeda H. *Cancer Res*. 1986; 46:6387–6392. [PubMed: 2946403]
5. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. *Science (Washington, DC, U S)*. 1994; 263:1600–1603.
6. Gref R, Domb A, Quellec P, Blunk T, Mueller RH, Verbavatz JM, Langer R. *Adv Drug Del Rev*. 1995; 16:215–233.
7. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. *Science (Washington, DC, U S)*. 1997; 276:1868–1871.
8. Langer R. *Nature (London)*. 1998; 392:5–10. [PubMed: 9579855]
9. Mammen M, Chio S-K, Whitesides GM. *Angew Chem, Int Ed*. 1998; 37:2755–2794.
10. Qiu LY, Bae YH. *Pharm Res*. 2006; 23:1–30. [PubMed: 16392022]
11. Fox ME, Szoka FC, Frechet JMJ. *Acc Chem Res*. 2009; 42:1141–1151. [PubMed: 19555070]
12. Chen B, Jerger K, Frechet JMJ, Szoka FC. *J Controlled Release*. 2009; 140:203–209.
13. Grayson SM, Godbey WT. *J Drug Targeting*. 2008; 16:329–356.
14. Duncan R. *Nat Rev Drug Discovery*. 2003; 2:347–360.
15. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. *Proc Natl Acad Sci U S A*. 2007; 104:15549–15554. [PubMed: 17875985]
16. Wu P, Malkoch M, Hunt JN, Vestberg R, Kaltgrad E, Finn MG, Fokin VV, Sharpless KB, Hawker CJ. *Chem Commun (Cambridge, U K)*. 2005:5775–5777.
17. Ihre HR, Padilla De Jesus OL, Szoka FC Jr, Frechet JMJ. *Bioconj Chem*. 2002; 13:443–452.
18. Breitenkamp K, Emrick T. *J Am Chem Soc*. 2003; 125:12070–12071. [PubMed: 14518974]

19. Becker ML, Remsen EE, Pan D, Wooley KL. *Bioconj Chem*. 2004; 15:699–709.
20. Such GK, Tjipto E, Postma A, Johnston APR, Caruso F. *Nano Lett*. 2007; 7:1706–1710. [PubMed: 17530811]
21. Cengelli F, Grzyb JA, Montoro A, Hofmann H, Hanessian S, Juillerat-Jeanneret L. *ChemMedChem*. 2009; 4:988–997. [PubMed: 19347834]
22. Tong GJ, Hsiao SC, Carrico ZM, Francis MB. *J Am Chem Soc*. 2009; 131:11174–11178. [PubMed: 19603808]
23. Lee S-M, Chen H, O'Halloran TV, Nguyen ST. *J Am Chem Soc*. 2009; 131:9311–9320. [PubMed: 19527027]
24. Lee J-S, Green JJ, Love KT, Sunshine J, Langer R, Anderson DG. *Nano Lett*. 2009; 9:2402–2406. [PubMed: 19422265]
25. Shen Y, Jin E, Zhang B, Murphy CJ, Sui M, Zhao J, Wang J, Tang J, Fan M, Van Kirk E, Murdoch WJ. *J Am Chem Soc*. 2010; 132:4259–4265. [PubMed: 20218672]
26. Helms B, Meijer EW. *Science (Washington, DC, U S)*. 2006; 313:929–930.
27. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. *Polym J (Tokyo, Jpn)*. 1985; 17:117–132.
28. Bosman AW, Janssen HM, Meijer EW. *Chem Rev (Washington, DC, U S)*. 1999; 99:1665–1688.
29. Montanez MI, Campos LM, Antoni P, Hed Y, Walter MV, Krull BT, Khan A, Hult A, Hawker CJ, Malkoch M. *Macromolecules*. 2010; 43:6004–6013.
30. Antoni P, Robb MJ, Campos L, Montanez M, Hult A, Malmstrom E, Malkoch M, Hawker CJ. *Macromolecules*. 2010; 43:6625–6631.
31. Killops KL, Campos LM, Hawker CJ. *J Am Chem Soc*. 2008; 130:5062–5064. [PubMed: 18355008]
32. Wu P, Feldman AK, Nugent AK, Hawker CJ, Scheel A, Voit B, Pyun J, Frechet MJM, Sharpless KB, Fokin VV. *Angew Chem, Int Ed*. 2004; 43:3928–3932.
33. Lee CC, Gillies ER, Fox ME, Guillaudeu SJ, Frechet MJM, Dy EE, Szoka FC. *Proc Natl Acad Sci U S A*. 2006; 103:16649–16654. [PubMed: 17075050]
34. Gillies ER, Dy E, Frechet MJM, Szoka FC. *Mol Pharm*. 2005; 2:129–138. [PubMed: 15804187]
35. Gillies ER, Frechet MJM. *J Org Chem*. 2004; 69:46–53. [PubMed: 14703377]
36. Gillies ER, Frechet MJM. *J Am Chem Soc*. 2002; 124:14137–14146. [PubMed: 12440912]
37. Grayson SM, Frechet MJM. *Macromolecules*. 2001; 34:6542–6544.
38. Boydston AJ, Holcombe TW, Unruh DA, Frechet MJM, Grubbs RH. *J Am Chem Soc*. 2009; 131:5388–5389. [PubMed: 19334732]
39. Zhang A, Zhang B, Waechtersbach E, Schmidt M, Schlueter AD. *Chem–Eur J*. 2003; 9:6083–6092. [PubMed: 14679520]
40. Lee CC, Grayson SM, Frechet MJM. *J Polym Sci, Part A Polym Chem*. 2004; 42:3563–3578.
41. Yoshida M, Fresco ZM, Ohnishi S, Frechet MJM. *Macromolecules*. 2005; 38:334–344.
42. Canilho N, Kaseemi E, Mezzenga R, Schlueter AD. *J Am Chem Soc*. 2006; 128:13998–13999. [PubMed: 17061861]
43. Helms B, Mynar JL, Hawker CJ, Frechet MJM. *J Am Chem Soc*. 2004; 126:15020–15021. [PubMed: 15547986]
44. Zhang M, Mueller AHE. *J Polym Sci, Part A: Polym Chem*. 2005; 43:3461–3481.
45. Jiang X, Lok MC, Hennink WE. *Bioconj Chem*. 2007; 18:2077–2084.
46. Tsarevsky NV, Bencherif SA, Matyjaszewski K. *Macromolecules*. 2007; 40:4439–4445.
47. Lutz J-F, Boerner HG, Weichenhan K. *Macromolecules*. 2006; 39:6376–6383.
48. Allen MJ, Wangkanont K, Raines RT, Kiessling LL. *Macromolecules*. 2009; 42:4023–4027. [PubMed: 20161406]
49. Cheng G, Boeker A, Zhang M, Krausch G, Mueller AHE. *Macromolecules*. 2001; 34:6883–6888.
50. Lu H, Wang J, Lin Y, Cheng J. *J Am Chem Soc*. 2009; 131:13582–13583. [PubMed: 19725499]
51. Morandi G, Pascual S, Montembault V, Legoupy S, Delorme N, Fontaine L. *Macromolecules*. 2009; 42:6927–6931.


52. Neugebauer D, Sumerlin BS, Matyjaszewski K, Goodhart B, Sheiko SS. *Polymer*. 2004; 45:8173–8179.
53. Sumerlin BS, Neugebauer D, Matyjaszewski K. *Macromolecules*. 2005; 38:702–708.
54. Gao H, Matyjaszewski K. *J Am Chem Soc*. 2007; 129:6633–6639. [PubMed: 17465551]
55. Hadjichristidis N, Pitsikalis M, Iatrou H, Pispas S. *Macromol Rapid Commun*. 2003; 24:979–1013.
56. Tsukahara Y, Mizuno K, Segawa A, Yamashita Y. *Macromolecules*. 1989; 22:1546–1552.
57. Tsukahara Y, Tsutsumi K, Yamashita Y, Shimada S. *Macromolecules*. 1990; 23:5201–5208.
58. Dziezok P, Sheiko SS, Fischer K, Schmidt M, Moller M. *Angew Chem, Int Ed*. 1998; 36:2812–2815.
59. Neiser MW, Okuda J, Schmidt M. *Macromolecules*. 2003; 36:5437–5439.
60. Neiser MW, Muth S, Kolb U, Harris JR, Okuda J, Schmidt M. *Angew Chem, Int Ed*. 2004; 43:3192–3195.
61. Yuan Y-Y, Du Q, Wang Y-C, Wang J. *Macromolecules*. 2010; 43:1739–1746.
62. Li C, Ge Z, Fang J, Liu S. *Macromolecules*. 2009; 42:2916–2924.
63. Li A, Lu Z, Zhou Q, Qiu F, Yang Y. *J Polym Sci, Part A Polym Chem*. 2006; 44:3942–3946.
64. Kolb HC, Finn MG, Sharpless KB. *Angew Chem, Int Ed*. 2001; 40:2004–2021.
65. Tornøe CW, Christensen C, Meldal M. *J Org Chem*. 2002; 67:3057–3064. [PubMed: 11975567]
66. Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. *Angew Chem, Int Ed*. 2002; 41:2596–2599.
67. Sumerlin BS, Tsarevsky NV, Louche G, Lee RY, Matyjaszewski K. *Macromolecules*. 2005; 38:7540–7545.
68. Gao H, Matyjaszewski K. *J Am Chem Soc*. 2007; 129:6633–6639. [PubMed: 17465551]
69. Tsarevsky NV, Bernaerts KV, Dufour B, Du Prez FE, Matyjaszewski K. *Macromolecules*. 2004; 37:9308–9313.
70. Campos LM, Killups KL, Sakai R, Paulusse JMJ, Damiron D, Drockenmuller E, Messmore BW, Hawker CJ. *Macromolecules*. 2008; 41:7063–7070.
71. Boerner HG, Beers K, Matyjaszewski K, Sheiko SS, Moeller M. *Macromolecules*. 2001; 34:4375–4383.
72. Golas PL, Matyjaszewski K. *Chem Soc Rev*. 2010; 39:1338–1354. [PubMed: 20309490]
73. Iha RK, Wooley KL, Nystrom AM, Burke DJ, Kade MJ, Hawker CJ. *Chem Rev (Washington, DC, U S)*. 2009; 109:5620–5686.
74. Hawker CJ, Wooley KL. *Science (Washington, DC, U S)*. 2005; 309:1200–1205.
75. Johnson JA, Finn MG, Koberstein JT, Turro NJ. *Macromol Rapid Commun*. 2008; 29:1052–1072.
76. Binder WH, Sachsenhofer R. *Macromol Rapid Commun*. 2007; 28:15–54.
77. Hawker CJ, Fokin VV, Finn MG, Sharpless KB. *Aust J Chem*. 2007; 60:381–383.
78. Xia Y, Kornfield JA, Grubbs RH. *Macromolecules*. 2009; 42:3761–3766.
79. Xia Y, Olsen BD, Kornfield JA, Grubbs RH. *J Am Chem Soc*. 2009; 131:18525–18532. [PubMed: 19947607]
80. Li Z, Ma J, Cheng C, Zhang K, Wooley KL. *Macromolecules*. 2010; 43:1182–1184.
81. Li Z, Zhang K, Ma J, Cheng C, Wooley KL. *J Polym Sci, Part A: Polym Chem*. 2009; 47:5557–5563.
82. Conrad RM, Grubbs RH. *Angew Chem, Int Ed*. 2009; 48:8328–8330.
83. Le D, Montebault V, Soutif JC, Rutnakornpituk M, Fontaine L. *Macromolecules*. 2010; 43:5611–5617.
84. Binder WH, Kluger C. *Macromolecules*. 2004; 37:9321–9330.
85. Binder WH, Kluger C, Josipovic M, Straif CJ, Friedbacher G. *Macromolecules*. 2006; 39:8092–8101.
86. Clark PG, Guidry EN, Chan WY, Steinmetz WE, Grubbs RH. *J Am Chem Soc*. 2010; 132:3405–3412. [PubMed: 20158251]
87. Otsuka H, Nagasaki Y, Kataoka K. *Adv Drug Delivery Rev*. 2003; 55:403–419.
88. O'Reilly RK, Joralemon MJ, Hawker CJ, Wooley KL. *New J Chem*. 2007; 31:718–724.



89. O'Reilly RK, Joralemon MJ, Hawker CJ, Wooley KL. *Chem--Eur J*. 2006; 12:6776–6786. [PubMed: 16800009]
90. O'Reilly RK, Joralemon MJ, Wooley KL, Hawker CJ. *Chem Mater*. 2005; 17:5976–5988.
91. Joralemon MJ, O'Reilly RK, Hawker CJ, Wooley KL. *J Am Chem Soc*. 2005; 127:16892–16899. [PubMed: 16316235]
92. Prasuhn DE Jr, Singh P, Strable E, Brown S, Manchester M, Finn MG. *J Am Chem Soc*. 2008; 130:1328–1334. [PubMed: 18177041]
93. Dolmans DEJGJ, Fukumura D, Jain RK. *Nat Rev Cancer*. 2003; 3:380–387. [PubMed: 12724736]
94. Bethea D, Fullmer B, Syed S, Seltzer G, Tian J, Rischko C, Gillespie L, Brown D, Gasparro FP. *J Dermatol Sci*. 1999; 19:78–88. [PubMed: 10098699]
95. Mal NK, Fujiwara M, Tanaka Y. *Nature (London, U K)*. 2003; 421:350–353. [PubMed: 12540896]
96. Skwarczynski M, Noguchi M, Hirota S, Sohma Y, Kimura T, Hayashi Y, Kiso Y. *Bioorg Med Chem Lett*. 2006; 16:4492–4496. [PubMed: 16806915]
97. McCoy CP, Rooney C, Edwards CR, Jones DS, Gorman SP. *J Am Chem Soc*. 2007; 129:9572–9573. [PubMed: 17636919]
98. Jiang MY, Dolphin D. *J Am Chem Soc*. 2008; 130:4236–4237. [PubMed: 18335942]
99. Agasti SS, Chompoosor A, You C-C, Ghosh P, Kim CK, Rotello VM. *J Am Chem Soc*. 2009; 131:5728–5729. [PubMed: 19351115]
100. Lee, H-i; Wu, W.; Oh, JK.; Mueller, L.; Sherwood, G.; Peteanu, L.; Kowalewski, T.; Matyjaszewski, K. *Angew Chem, Int Ed*. 2007; 46:2453–2457.
101. Pastine SJ, Okawa D, Zettl A, Frechet JMJ. *J Am Chem Soc*. 2009; 131:13586–13587. [PubMed: 19736938]
102. Kim H-C, Hartner S, Behe M, Behr Thomas M, Hampp Norbert A. *J Biomed Opt*. 2006; 11:34024. [PubMed: 16822073]
103. Haertner S, Kim H-C, Hampp N. *J Polym Sci, Part A Polym Chem*. 2007; 45:2443–2452.
104. Lewis WG, Magallon FG, Fokin VV, Finn MG. *J Am Chem Soc*. 2004; 126:9152–9153. [PubMed: 15281783]
105. Rodionov VO, Fokin VV, Finn MG. *Angew Chem, Int Ed*. 2005; 44:2210–2215.
106. Rodionov VO, Presolski SI, Diaz DD, Fokin VV, Finn MG. *J Am Chem Soc*. 2007; 129:12705–12712. [PubMed: 17914817]
107. Rodionov VO, Presolski SI, Gardinier S, Lim Y-H, Finn MG. *J Am Chem Soc*. 2007; 129:12696–12704. [PubMed: 17914816]
108. Ngo JT, Champion JA, Mahdavi A, Tanrikulu IC, Beatty KE, Connor RE, Yoo TH, Dieterich DC, Schuman EM, Tirrell DA. *Nat Chem Biol*. 2009; 5:715–717. [PubMed: 19668194]
109. Dieterich DC, Link AJ, Graumann J, Tirrell DA, Schuman EM. *Proc Natl Acad Sci U S A*. 2006; 103:9482–9487. [PubMed: 16769897]
110. Speers AE, Cravatt BF. *Chem Biol*. 2004; 11:535–546. [PubMed: 15123248]
111. Prescher JA, Bertozzi CR. *Nat Chem Biol*. 2005; 1:13–21. [PubMed: 16407987]
112. Hong V, Presolski SI, Ma C, Finn MG. *Angew Chem, Int Ed*. 2009; 48:9879–9883.
113. Kolonko EM, Kiessling LL. *J Am Chem Soc*. 2008; 130:5626–5627. [PubMed: 18393495]




**Figure 1.** Schematic depiction of the “graft-through and click-to” approach described in this work. **A:** We start with a bivalent macromonomer (**2**) and perform “graft-through” ROMP with catalyst **1** followed by *in situ* chloride-azide exchange. **B:** The resulting azido-bivalent-brush polymer is then functionalized with an alkyne by click chemistry in a “click-to” step. If the alkyne partner is a drug molecule linked via a cleavable linker, then the resulting brush polymer can release the drug in response to an external stimulus. In this work we demonstrate controlled release of the anticancer agent doxorubicin (**DOX**) in response to 365 nm UV light.




**Figure 2.**

**A:** Representative GPC traces for  $nN_3$  bivalent-brush polymer samples show monomodal molecular weight distributions, low polydispersities, and high conversions. **B:** Hydrodynamic diameter histograms for selected  $nN_3$  polymers obtained from DLS measurements using the CONTIN fitting algorithm. The particle sizes increase with increasing DP and are varied over a wide range by adjusting the ratio of MM to catalyst (**6:1**) before graft-through ROMP.




**Figure 3.** FTIR spectra of  $n\text{N}_3$  bivalent-brush polymers normalized to the strong PEG ether (C-O-C) antisymmetric stretch absorbance. The relative amount of azide is approximately the same for each  $n$  value which suggests that chloride-azide exchange is not sterically limited with increased DP.




**Figure 4.** A: Prep-HPLC traces of crude CuAAC mixtures which depict similar conversion for each  $n$  value. A (inset): Progress of CuAAC coupling of **9** to **100N<sub>3</sub>** monitored by LC-MS. B. FTIR spectra of **50N<sub>3</sub>** and **50DOX** confirming complete loss of azide after CuAAC.






**Figure 5.**


**A:** Time-dependent UV photolysis of **100DOX** monitored by LC-MS; after 10 min irradiation ~70% of free **DOX** was released. A minor product (labelled “\*”, see Scheme 5) was also observed at longer irradiation times. **B:** Viability of MCF-7 human breast cancer cells treated with free **DOX**, **100N<sub>3</sub>** bivalent-brush polymer, and drug-loaded **100DOX** polymer both with and without UV irradiation. Data points were fit to a sigmoidal function and the half-maximum inhibitory concentrations (IC<sub>50</sub>) are shown for **DOX** and the photocleaved **100DOX**. The *x*-axis labels refer to the concentration of both free and polymer-conjugated drug.




**Scheme 1.**  
Synthesis of PEG-norbornene-chloride MM **6**.

**Scheme 2.**

Synthesis of azido-bivalent-brush polymers ( $nN_3$ ) by ROMP and chloride-azide exchange.




**Scheme 3.**  
Synthesis of **DOX**-nitrobenzyloxycarbonyl (NBOC)-alkyne derivative **9** for click chemistry and photorelease of **DOX**.

**Scheme 4.**

CuAAC coupling of **9** to  $nN_3$  brush using tris(hydroxypropyltriazolylmethyl)amine (**THPTA**) ligand, copper(II) sulfate, and sodium ascorbate as an *in situ* reductant.



**Scheme 5.**

Photolysis of *n*DOX polymers gives carbamic acid **10**. Decarboxylation of **10** yields free DOX as the major product while intramolecular trapping provides DOX-carbamate derivative **11** as a minor product (Figure 5A, labelled “\*”). Reactive nitrosobenzaldehyde photoproducts remain bound to the polymer core after photolysis.

**Table I**

Characterization of  $n\mathbf{N}_3$  bivalent brush polymers by GPC (room temp., 0.2 M LiBr in DMF, 1 mL/min) and DLS (aqueous).

$n$ (theo.) <sup>[a]</sup>	DP <sup>[b]</sup>	$M_n$ (GPC, kDa)	PDI	$R_h$ <sup>[c]</sup> /nm
10	10	34.1	1.11	3.1 (0.3)
30	32	109	1.04	6.3 (0.8)
50	53	180	1.07	6.9 (0.9)
70	70	238	1.14	7.3 (0.3)
80	80	272	1.14	7.5 (0.8)
100	101	343	1.06	11 (1)
300	295	1,000	1.11	15 (1)
400	575	1,960	1.27	25 (2)

<sup>[a]</sup> ratio of MM to catalyst (i.e. theoretical DP). This number is used to identify  $n\mathbf{N}_3$  and  $\mathbf{DOXN}_3$  samples throughout the text,

<sup>[b]</sup> DP observed derived from  $M_n(\text{GPC})/M_n(\text{MM})$ ,

<sup>[c]</sup> hydrodynamic radii measured by dynamic light scattering (DLS). DLS correlation functions were fit using the CONTIN algorithm.